- FDA approves generic versions of Plavix
- FDA OKs Abilify as maintenance treatment for bipolar disorder
- As innovaters prep for patent cliff, generics prosper from patent losses
- FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux
- Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment
SHANGHAI — Drug maker Bristol-Myers Squibb is opening a new testing facility in China under collaboration with a local company there, Bristol said Monday.
WuXi PharmaTech will build, equip and operate the 25,000-sq.-ft. lab in Shanghai to store and test stability samples and perform other services for Bristol.
“This new agreement expands our already productive relationship with Bristol-Myers Squibb, a valued customer for many years,” WuXi CEO and chairman Ge Li said. “We will continue to help them to improve their [research and development] productivity with our innovation-driven, cost-effective and fully integrated R&D service platform.”